Safety and Outcomes analysis: transcatheter implantation of autologous angiogenic cell precursors for the treatment of cardiomyopathy

Stem cell transplantation is an emerging therapy for severe cardiomyopathy, proffering stem cell recruitment, anti-apoptosis, and proangiogenic capabilities.

Jane R. Schubart, Amirhossein Zare, Roberto M. Fernandez-de-Castro, Hector Rosario Figueroa, Ina Sarel, Kelly Tuchman, Kaitlyn Esposito, Fraser C. Henderson & Ernst von Schwarz

Cytotherapy 2013

Peripheral blood-derived autologous stem cell therapy for the treatment of patients with late-stage peripheral artery disease-results of the short- and long-term follow-up

G.V. Szabó, Z. Kövesd, J. Cserepes, J. DaróczyM. Belkin M, and G. Acsády

BioProcessing Journal 2007

Challenges in the Development of Autologous Cell Therapy Products

Y. Porat, D. Belkin, A. Belleli, J. Elkayam, D. Shimoni, S. Porozov, I. Sarel, I. Ash, and V. Fulga

Hemostemix ACP-01 Publication

Autologous Stem Cell Treatment For CLI Patients With No Revascularization Options
(An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup)

Jonathan Misskey MD MHPE FRCSC, Lynn Cunada, RN, Kyle Makofka, Alan Jacobs MSEE MD PhD,
Thomas Lindsay MDCM, MSc, FRCSC, York N. Hsiang, MB ChB, MHSc., FRCSCS

Asian Annals

Intramyocardial Angiogenic Cell Precursor Injection for Cardiomyopathy
Kitipan V Arom, Permyos Ruengsakulrach and Vibul Jotisakulratana
Asian Cardiovasc Thorac Ann 2008;16:143-148

BJH research paper

Isolation of an adult blood-derived progenitor cell population
capable of differentiation into angiogenic, myocardial and
neural lineages

Panama College of Cell Science

Transcoronary Injection of Angiogenic Cells Precursors an Autologous Stem Cell in Ischemic Cardiomyopathy: A Clinical study of 106 cases in Thailand

Angiogenic Precursor Cell Treatment of Critical Limb Ischemia Decreases Ulcer Size, Amputation and Death Rate: Re-Examination of phase II ACP NO-CLI Trial Data

Critical limb ischemia has a prevalence in the US of 1.33%, with mortality 15-20%
and major amputation 10-40% per year. Stem cell treatment has emerged as a treatment option for
the 45% of patients for whom revascularization procedures are not possible.
Objective: This study re-examines the data of the Phase II clinical treatment of no opti